Navigation Links
New Engineered Drug Shows Promise in Treating Lymphocytic Leukaemia

A recent research has found that a new type of engineered drug may have the potential to treat chronic lymphocytic leukaemia.

The study by researchers at the Ohio State University Comprehensive Cancer Center was published online in the journal Blood.

The research has established that an engineered drug candidate is promising in treating lymphocytic leukemia in both test tube and early animal tests.

The agent represents a new class of agents called small modular immunopharmaceuticals. This agent, which is called CD37-SMIP, targets a protein called CD37 on the surface of these leukemia cells.

The study shows that the agent can successfully attach to the protein on the leukemia cells and destroy them. It works both by activating the cells' self-destruction and by causing a particular class of immune cells to attack them.

In an animal model, the agent worked uniformly over and above the drug rituximab, now routinely used to treat chronic lymphocytic leukemia (CLL) patients. Rituximab targets a different protein on leukemia cells.

"Our findings have significant implications for the treatment of CLL and related malignancies," says principal investigator John C. Byrd, director of the hematologic malignancies program at Ohio State 's James Cancer Hospital and Solove Research Institute.

Overall, Byrd says, "the findings point out that this could be an effective agent for treating CLL and other malignancies, such as non-Hodgkin's lymphoma and acute lymphoblastic leukemia when they have expression of the CD37 protein."

The laboratory portion of the study used CLL cells from patients, laboratory-grown non-Hodgkin's lymphoma cells and acute lymphocytic leukemia cells.

This research showed that the agent kills leukemia cells directly by triggering their self-destruction through the process of apoptosis.

The study also found that thi s self-destruction happens differently from how other drugs cause apoptosis. Most drugs cause cells to self-destruct by triggering a cell mechanism that requires enzymes called caspases. This new agent, however, works through a mechanism that does not call for caspases.

"This is exciting because it means that this agent may benefit patients who are resistant to other CLL drugs," says co-author Natarajan Muthusamy, a research scientist with Ohio State's Comprehensive Cancer Center. "It also suggests that it might work well in combination with other drugs, as well as alone."

The findings also show that after the agent joins with the cancer cells, it attracts immune cells called natural killer cells, which also devastate the leukemia cells.


'"/>




Related medicine news :

1. Regulators Object Drug Produced from Genetically Engineered Farm Animals
2. Engineered Tissue Implants benefited Knee Injured patients
3. Indian American have Genetically Engineered Edible Cottonseed
4. USDA Gives Go-Ahead to Market Controversial Genetically Engineered Rice, LL601
5. Xylitol To Be Produced By Genetically Engineered E. Coli
6. Genetic-Engineered Cows Resist Mad Cow Disease
7. Researchers Explore the Effect of Engineered Immune Cells on HIV
8. Tissue Engineered Scaffolding Allows Reproduction of Cartilage Tissue
9. Experimental treatment for Ebola Virus Shows promising results in mice
10. New Prostate Cancer Vaccine Shows Promise
11. Ebola Treatment Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology: